nach oben

Investigational New Drugs

Erschienen in:

22.07.2022 | Research

Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome

verfasst von: Yang He, Weijin Fang, Zuojun Li, Chunjiang Wang

Erschienen in: Investigational New Drugs | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Summary

Knowledge of dasatinib-induced nephrotic syndrome is largely based on case reports. The clinical features of dasatinib-induced nephrotic syndrome are unknown. We collected case reports of 25 patients with nephrotic syndrome and analyzed their clinical characteristics. Overall, the onset of nephrotic syndrome ranged from 10 days to 5 years after dasatinib administration. Nine patients (36.0%) had clinical symptoms, mainly periorbital edema and lower-extremity edema. Serum albumin ranged from 1.2 g/dL to 3.7 g/dL in 10 patients (38.5%). The 24-h urine protein values ranged from 3.54 g/day to 118 g/day. Kidney biopsy of 13 patients (52.0%) mainly showed focal foot process effacement, mesangial hyperplasia, endothelial cell damage and focal segmental glomerulosclerosis. Proteinuria resolved or recovered after dasatinib discontinuation or dose reduction or switching to other tyrosine kinase inhibitors (TKIs).

Rossari F, Minutolo F, Orciuolo E (2008) Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol 11(1):84. https://doi.org/10.1186/s13045-018-0624-2CrossRef

Levêque D, Becker G, Bilger K, Natarajan-Amé S (2020) Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. Clin Pharmacokinet 59(7):849–856. https://doi.org/10.1007/s40262-020-00872-4

Montero JC, Seoane S, Ocaña A, Pandiella A (2011) Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 17(17):5546–5552. https://doi.org/10.1158/1078-0432.CCR-10-2616CrossRefPubMed

Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H et al (2014) Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 123(15):2317–2324. https://doi.org/10.1182/blood-2013-10-532341CrossRefPubMedPubMedCentral

Moslehi JJ, Deininger M (2015) Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol 33(35):4210–4218. https://doi.org/10.1200/JCO.2015.62.4718CrossRefPubMedPubMedCentral

Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P et al (2011) Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 17(9):2977–2986. https://doi.org/10.1158/1078-0432.CCR-10-2879CrossRefPubMedPubMedCentral

Mahalingasivam V, Booth J, Sheaff M, Yaqoob M (2018) Nephrotic syndrome in adults. Acute Med 17(1):36–43PubMed

Mandac Rogulj I, Matišić V, Arsov B, Boban L, Juginović A, Molnar V, Primorac D (2019) Dasatinib-induced nephrotic syndrome: a case of phenoconversion. Croat Med J 60(3):250–254. https://doi.org/10.3325/cmj.2019.60.250CrossRefPubMedPubMedCentral

Wallace E, Lyndon W, Chumley P, Jaimes EA, Fatima H (2013) Dasatinib-induced nephrotic-range proteinuria. Am J Kidney Dis 61(6):1026–1031. https://doi.org/10.1053/j.ajkd.2013.01.022CrossRefPubMed

10.

Ruebner RL, Copelovitch L, Evageliou NF, Denburg MR, Belasco JB, Kaplan BS (2014) Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol 29(5):863–869. https://doi.org/10.1007/s00467-013-2696-0CrossRefPubMed

11.

Lim YT, Kim YJ, Park YH, Hah JO, Lee JM (2016) A Case of Dasatinib-Induced Nephrotic Syndrome in a Child with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Yonsei Med J 57(2):532–533. https://doi.org/10.3349/ymj.2016.57.2.532CrossRefPubMedPubMedCentral

12.

Ersoy Yesil E, Sit D, Kayabasi H, Zerenler Gursoy F, Demirbas MB, Ocak Serin S (2021) A case of dasatinib-induced focal segmental glomerulosclerosis in a patient with Philadelphia chromosome positive chronic myeloid leukemia. Nephrol Ther 17(1):53–56. https://doi.org/10.1016/j.nephro.2020.09.007CrossRefPubMed

13.

ElShaer A, Almasry M, Alawar M, Masoud H, El Kinge AR (2021) Dasatinib-Induced Nephrotic Syndrome: A Case Report. Cureus 13(12):e20330. https://doi.org/10.7759/cureus.20330CrossRefPubMedPubMedCentral

14.

Hirano T, Hashimoto M, Korogi Y, Tsuji T, Miyanaka K, Yamasaki H, Tsuda H (2016) Dasatinib-induced nephrotic syndrome. Leuk Lymphoma 57(3):726–727. https://doi.org/10.3109/10428194.2015.1075020CrossRefPubMed

15.

Ochiai S, Sato Y, Minakawa A, Fukuda A, Fujimoto S (2019) Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report. BMC Nephrol 20(1):87. https://doi.org/10.1186/s12882-019-1273-6CrossRefPubMedPubMedCentral

16.

Koinuma K, Sakairi T, Watanabe Y, IIzuka A, Watanabe M, Hamatani H, Nakasatomi M, Ishizaki T, Ikeuchi H, Kaneko Y, Hiromura K (2020) A case of long-term dasatinib-induced proteinuria and glomerular injury. CEN Case Rep 9(4):359–364. https://doi.org/10.1007/s13730-020-00484-8CrossRefPubMedPubMedCentral

17.

Kawaguchi H, Tamura Y, Suzuki S, Asano-Murakoshi T, Nonoyama S (2017) Cytomegalovirus infection- and dasatinib-induced proteinuria in Ph+ALL. Pediatr Int 59(6):740–741. https://doi.org/10.1111/ped.13251CrossRefPubMed

18.

De Luca ML, Carmosino I, Stefanizzi C, Campanelli M, De AF, Cesini L, Latagliata R, Alimena G (2016) Nephrotic Proteinuria Developed under Dasatinib Treatment in a Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature. Ann Hematol Oncol 3(8):1106

19.

Piscitani L, Sirolli V, Di Liberato L, Morroni M, Bonomini M (2020) Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations. Int J Mol Sci 21(14):4878. https://doi.org/10.3390/ijms21144878CrossRefPubMedCentral

20.

Stanchina M, McKinnell Z, Park JH, Stein EM, Cai SF, Taylor J (2020) BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon. Leuk Res Rep 14:100211. https://doi.org/10.1016/j.lrr.2020.100211CrossRefPubMedPubMedCentral

21.

Li GH, Liu C, Qin WW, Zhou NC, Guo HP, Yan XQ, Ji YR, Chen Y, Liu L, Liang YM (2021) Dasatinib-induced massive proteinuria: a case report. Zhonghua Xue Ye Xue Za Zhi. 42(8):692. Chinese. https://doi.org/10.3760/cma.j.issn.0253-2727.2021.08.017

22.

Chow C, Abraham S (2015) Dasatinib induced chylothorax and nephrotic syndrome in a pediatric patient.Pediatric Blood and Cancer 62(Suppl.2):S71

23.

Loi V, Lepori N, Floris M, Asunis AM, Angioi A, Cao R, Atzeni A, Piras D, Cabiddu G, Pani A (2018) Dasatinib-associated FSGS: A case report. J Am Soc Nephrol 29:abstr 808

24.

Koshida T, Suzuki H, Kihara M, Nogi C, Suzuki Y (2017) Nephrotic syndrome in dasatinib-treated patients with chronic myeloid leukemia. J Am Soc Nephrol 28:abstr 410

25.

Muller-Hansma AHG, van der Lugt J, Zwaan CM (2017) Nephrotic syndrome under treatment with dasatinib: be aware of a possible adverse drug reaction. Neth J Med 75(10):428–431PubMed

26.

Orth SR, Ritz E (1998) The nephrotic syndrome. N Engl J Med 338(17):1202–1211. https://doi.org/10.1056/NEJM199804233381707CrossRefPubMed

27.

Calizo RC, Bhattacharya S, van Hasselt JGC, Wei C, Wong JS, Wiener RJ, Ge X, Wong NJ, Lee JJ, Cuttitta CM et al (2019) Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity. Nat Commun 10(1):2061. https://doi.org/10.1038/s41467-019-09936-xCrossRefPubMedPubMedCentral

28.

Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15(19):6232–6240. https://doi.org/10.1158/1078-0432.CCR-09-0224CrossRefPubMed

29.

Wiggins RC (2007) The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71(12):1205–1214. https://doi.org/10.1038/sj.ki.5002222CrossRefPubMed

30.

Sato Y, Wharram BL, Lee SK, Wickman L, Goyal M, Venkatareddy M, Chang JW, Wiggins JE, Lienczewski C, Kretzler M, Wiggins RC (2009) Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol 20(5):1041–1052. https://doi.org/10.1681/ASN.2007121328CrossRefPubMedPubMedCentral

31.

Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358(11):1129–1136. https://doi.org/10.1056/NEJMoa0707330CrossRefPubMedPubMedCentral

32.

Wada T, Ishimoto T, Nakaya I, Kawaguchi T, Sofue T, Shimizu S, Kurita N, Sasaki S, Nishiwaki H, Koizumi M et al (2021) A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020. Clin Exp Nephrol 25(12):1277–1285. https://doi.org/10.1007/s10157-021-02098-5CrossRefPubMed

Titel: Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome
verfasst von: Yang He
Weijin Fang
Zuojun Li
Chunjiang Wang
Publikationsdatum: 22.07.2022
Verlag: Springer US
Erschienen in: Investigational New Drugs / Ausgabe 5/2022
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-022-01288-6

Springer Medizin

Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome

Summary

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Onkologie

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma

Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma

A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer

Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report

MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer

Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Update Onkologie